Overview

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been approved to be used together.
Phase:
Phase 3
Details
Lead Sponsor:
CryoLife, Inc.
Collaborator:
Duke Clinical Research Institute
Treatments:
Apixaban
Warfarin